References

1.   1.      Acharya G, Al-Sammarai MT, Patel N, et al. A randomized, controlled trial comparing effect of oral misoprostol and intra-venous syntocinon on intra-operative blood loss during cesarean section. Acta Obstet Gynecol Scand. 2001;80:245-50.

2.      Munn MB, Owen J, Vincent R, et al. Comparison of two oxytocin regimens to prevent uterine atony at cesarean delivery: a ran-domized controlled trial. Obstet Gynecol. 2001;98:386-90.

3.      Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med. 2001;344:38-47.

4.      Zhao Y, Li X, Peng Y. Clinical study on reduction of postpartum bleeding in cesarean section by misoprostol. Zhonghua Fu Chan KeZaZhi. 1998;33:403-5.

5.      Lokugamage AU, Paine M, Bassaw-Balroop K, et al. Active management of the third stage at caesarean section: a randomised controlled trial of misoprostol versus syntocinon. Aust N Z J ObstetGynaecol. 2001;41:411-4.

6.      Hamm J, Russell Z, Botha T, et al. Buccal misoprostol to prevent hemorrhage at cesarean delivery: a randomized study. Am J Obstet Gynecol. 2005;192:1404-6.

7.      Vimala N, Mittal S, Kumar S. Sublingual misoprostol versus oxytocin infusion to reduce blood loss at cesarean section. Int J Gynaecol Obstet. 2006;92:106-10.

8.      Lapaire O, Schneider MC, Stotz M, et al. Oral misoprostol versus intravenous oxytocin in reducing blood loss after emergency cesarean delivery. Int J Gynaecol Obstet. 2006;95:2-7.

9.      Patel A, Goudar SS, Geller SE, et al. Drape estimation versus visual assessment for estimating postpartum hemorrhage. Int J Gynaecol Obstet. 2006;93:220-4.

10.  Fekih M, Jnifene A, Fathallah K, et al. Benefit of misoprostol for prevention of postpartum hemorrhage in cesarean section: a randomized controlled trial [Article in French]. J Gynecol Obstet Biol Reprod. 2009;38:588-93.

11.  Hofmeyr GJ, Giilmezoglu AM, Novikova N, et al. Misoprostol to prevent and treat postpartum hemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects. Bull World Health Organ. 2009;87:666-77.

12.  Tang OS, Schweer H, Seyberth HW, et al. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod. 2002;17:332-6.

13.  Schaff EA, DiCenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual adminis-tration. Contraception. 2005;71:22-5.

14.  Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharma-cokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007;99:S160-7.

15.  Gulmezoglu AM, Forna F, Villar J, et al. Prostaglandins for prevention of postpartum hemorrhage. Cochrane Database Syst Rev. 2007;Issue 3, Art No: CD000494. doi: 10.1002/14651858.

16.  Alfirevic Z, Blum J, Walraven G, et al. Prevention of postpartum hemorrhage with misoprostol. Int J Gynaecol Obstet. 2007. S198-201.

17.  World Health Organization. WHO recommendations for the prevention of postpartum hemorrhage. Geneva: World Health Organization; 2007. p. 40. WHO/MPS/07.06.

18.  Eftekhari N, Doroodian M, Lashkarizadeh R. The effect of sub-lingual misoprostol versus intravenous oxytocin in reducing bleeding after caesarean section. J ObstetGynaecol. 2009;29: 633-6.

Corresponding Author

Dr Tabassum Ahmed

Assistant Professor, Dept. (Obst&Gynae)

NMCH, Patna, Bihar